Table 2.
Therapeutic interventions in the study populations.
| Historical control group | PMX-DHP group | p-value | |
|---|---|---|---|
| PMX-DHP therapy | 0 | 41 | |
| Time to PMX-DHP (days) | – | 6.3 ± 11.0 | |
| CS therapy | 36 (100) | 41 (100) | >0.99 |
| CS alone | 11 (31) | 8 (20) | 0.392 |
| CS + ISAs | 25 (69) | 33 (80) | 0.392 |
| CS + cyclophosphamide | 9 (25) | 10 (24) | >0.99 |
| CS + cyclosporine | 10 (28) | 7 (17) | 0.392 |
| CS + cyclophosphamide + cyclosporine or tacrolimus | 6 (16) | 16 (39) | 0.056 |
| Sivelestat sodium hydrate | 20 (56) | 26 (63) | 0.639 |
| Mechanical ventilation | 16 (45) | 23 (56) | 0.428 |
| IPPV | 15 (42) | 19 (46) | 0.855 |
| NPPV | 1 (3) | 4 (10) | 0.364 |
Data are expressed as means ± standard deviations or number (%) of patients. The p-values refer to comparisons between historical control group and PMX-DHP group.
CS, corticosteroids; IPPV, invasive positive pressure ventilation; ISAs, immunosuppressive agents; NPPV, noninvasive positive pressure ventilation; PMX-DHP, direct hemoperfusion using polymyxin B-immobilized fiber column.